Skip to content

For research use only. Not for human or animal consumption. Ships to US addresses only.

Research News

Nov 20, 2026 · 2 min readIndustry NewsClinical Trials

Ascletis Files IND for an Oral Quadruple Peptide Agonist

Ascletis submitted a US IND for ASC36_37o, a once-weekly oral amylin plus GLP-1/GIP/glucagon peptide combination. Data so far are preclinical.

Ascletis Pharma (HKEX: 1672) announced on 17 November 2026 that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration for ASC36_37o, a once-weekly oral fixed-dose combination of two peptides. The company's press release does not say whether the FDA has accepted or cleared the application.

What was announced

ASC36_37o combines two in-house peptides: ASC36, an amylin receptor agonist, and ASC37, a triple agonist of the GLP-1, GIP and glucagon receptors. Together the combination targets four receptors. The company describes it as a potentially first-in-class once-weekly oral product for obesity; that characterization is the company's own.

Ascletis says both peptides were discovered with an AI-assisted, structure-based drug discovery approach, and that the tablet uses its POTENT oral peptide delivery platform, which is designed to improve bioavailability and reduce pharmacokinetic variability by enabling absorption in both the stomach and the intestine.

Preclinical data reported by the company

All figures below are from the company's press release and come from animal studies, not from people.

  • Non-human primates (steady state): half-life of up to 200 hours for ASC36 and up to 96 hours for ASC37. Oral bioavailability was reported as above 10% for ASC36 and at least 9.1% for ASC37.
  • Diet-induced obese rats: the combination produced about 69% greater body weight reduction than ASC37 alone and about 192% greater reduction than ASC36 alone, in a head-to-head comparison.

The release does not provide the underlying study designs, group sizes or dosing in detail, and the data have not been published in a peer-reviewed journal. Results in rodents and primates often do not translate to humans.

Context

Ascletis has also recently started a US phase 1 study of ASC36o, an oral once-weekly amylin receptor agonist, with topline human pharmacokinetic data expected by the end of 2026. Separately, the company's ASC30, an oral small-molecule GLP-1 receptor agonist, is in two global phase 3 obesity studies, according to the release.

Amylin receptor agonists such as cagrilintide, and multi-receptor incretin agonists such as the GLP-1/GIP/glucagon class, are an active area of obesity research. An oral weekly peptide would be notable because peptides generally have low oral bioavailability. Whether this combination reaches humans at meaningful exposure is the question the phase 1 data will begin to answer.

What comes next

The next milestones are the FDA's handling of the IND and the first human pharmacokinetic results from the ASC36o phase 1 study, which Ascletis expects by the end of 2026.

Sources

Sources

  1. Ascletis press release, PR Newswire, 17 Nov 2026

For research use only. Not for human or animal consumption. This article summarizes published research for scientific information only. It is not medical advice and makes no claim about any use in people or animals. These products have not been evaluated or approved by the U.S. Food and Drug Administration (FDA). They are not intended to diagnose, treat or prevent any disease.